Prieto, I. (Inés)

Filtering

1991 - 199942000 - 20091

Settings

Author search.filters.isAuthorOfPublication.310096c9-cf39-43e6-99b6-171bec6de802

Search Results

Now showing 1 - 5 of 5
  • Thumbnail Image
    Epigenetic Signatures Associated with Different Levels of Differentiation Potential in Human Stem Cells
    (Public Library of Science, 2009) Cigudosa, J.C. (Juan Cruz); Roman-Gomez, J. (José); Ballestar, E. (E.); Aranda, P. (P.); Prieto, I. (Inés); Andreu, E.J. (Enrique José); Siebert, R. (Reiner); Esteller, M. (Manel); Prosper-Cardoso, F. (Felipe); Aguirre-Ena, X. (Xabier); Martin-Subero, J.I. (Jose Ignacio)
    The therapeutic use of multipotent stem cells depends on their differentiation potential, which has been shown to be variable for different populations. These differences are likely to be the result of key changes in their epigenetic profiles.
  • Thumbnail Image
    Insights on the amino acid side-chain interactions of a synthetic T-cell determinant
    (Elsevier, 1991) Borras-Cuesta, F. (Francisco); Prieto, I. (Inés); Sarobe, P. (Pablo); Guillet, J.G. (J. G.); Golvano, J.J. (José Javier); Guillaume, J.L. (J. L.); Szabo, A. (A); Lasarte, J.J. (Juan José)
    The effect of single amino acid substitutions at positions 18 and 20 on the T-cell determinant (TD) character of peptide p12-26 from lambda repressor protein and on its recognition by a monoclonal antibody was studied by means of 40 synthetic peptides of a length of 15 amino acids. ELISA competition experiments showed that the identity of amino acid at position 20 is very important for antibody recognition, whereas that of amino acid at position 18 is much less important. In contrast, both Leu 18 and Ala 20 are important residues in defining the TD character of peptide p12-26. The most tolerated replacements, ordered in increasing disrupting power are: Ala 20 by Cys, Ser or Gly and Leu 18 by Ile or Val. Any other amino acid replacement completely abolishes the TD capacity of peptide p12-26. The peptides used in this study were synthesized using a multiple solid-phase peptide synthesizer newly designed. Their purity was very high as shown by amino acid sequence experiments.
  • No Thumbnail Available
    Synthesis and evaluation of new Reissert analogs as HIV-1 RT inhibitors. 2. Benzo[f]quinoline and pyridine derivatives
    (Informa Healthcare, 1997) Borras-Cuesta, F. (Francisco); Alvarez, E. (E.); Sanmartin-Grijalba, C. (Carmen); Nadal, E. (Ernest); Font, M. (María); Prieto, I. (Inés); Monge, A. (Antonio); Martinez-Irujo, J.J. (Juan José); Sarobe, P. (Pablo); Santiago, E. (Esteban); Ruiz, I. (I); Lasarte, J.J. (Juan José)
    The synthesis and preliminary evaluation of new benzo[f]quinoline and pyridine derivatives, obtained by application of the Reissert method and its modifications, as HIV-1 RT inhibitors and anti-infectives are presented. The most active products against HIV-1 RT wild type are the ethyl 2-cyano-1,2-dihydrobenzo[f]quinoline-1-carboxylate 2b, propyl 2-cyano-1,2-dihydrobenzo[f]quinoline-1-carboxylate 2c, and 2-cyano-1-(2'-furoyl)-1,2-dihydrobenzo[f]quinoline 2n, which maintain their activity against the mutant type P236L, resulting inactive against the Y181C type. Using the data previously obtained by our research team for analogous series derived from quinoline as reference, the compounds which have now been obtained present an increase in the cytotoxic character attributable to the introduction of a benzene ring fused with the quinoline base nucleus, as well as a decrease of the activity as HIV-1 RT inhibitors when the quinoline benzenic ring is eliminated.
  • Thumbnail Image
    Enhancement of peptide immunogenicity by insertion of a cathepsin B cleavage site between determinants recognized by B and T cells
    (Elsevier, 1993) Borras-Cuesta, F. (Francisco); Larrea, E. (Esther); Prieto, I. (Inés); Prieto, J. (Jesús); Sarobe, P. (Pablo); Golvano, J.J. (José Javier); Gullon, A. (Arturo); Lasarte, J.J. (Juan José)
    The insertion of two lysine residues (cleavage sites of cathepsin B) at the boundary of a peptide recognized by B cells (BD) and a class-II- presentable sequence (TDh) enhanced the anti-BD antibody induction capacity of this type of peptide construct, as well as production of IL2. It is postulated that these lysines generate a neoprocessable site which helps in release of the TDh moiety from the construct, enabling its presentation to class II molecules, an essential step in clonal expansion of the antibody-producing B cell after internalization of the construct via the BD moiety.
  • No Thumbnail Available
    Synthesis and evaluation of new Reissert analogs as HIV-1 reverse transcriptase inhibitors. 1. Quinoline and quinoxaline derivatives
    (Gordon and Breach, 1997) Merino, I. (Isidro); Cuartero, A. (A); Alberdi, E. (Elena); Borras-Cuesta, F. (Francisco); Fidalgo, M.J. (M. J.); Alvarez, E. (E.); Sanmartin-Grijalba, C. (Carmen); Nadal, E. (Ernest); Font, M. (María); Prieto, I. (Inés); Losa, M.J. (M.J.); Monge, A. (Antonio); Martinez-Irujo, J.J. (Juan José); Sarobe, P. (Pablo); Santiago, E. (Esteban); Ruiz, I. (I); Lasarte, J.J. (Juan José)
    The synthesis and preliminary evaluation of new quinoline and quinoxaline derivatives (obtained by applying the original Reissert method, conveniently modified) as HIV-1 Reverse Transcriptase (RT) inhibitors are presented in this paper; likewise, the first structure-activity relationships are also proposed. Propyl 2-cyano-1(2H)-quinolin-carboxylate 2e, isopropyl 2-cyano-1 (2H)-quinolincarboxylate 2f, butyl 2-cyano-1 (2H)-quinolincarboxylate 2g and isobutyl 2-cyano-1 (2H)-quinolincarboxylate 2h have been selected as lead compounds. These compounds are active against the HIV-1 RT mutant type P236L (2f, IC50 = 1.2 microM) and present activity as anti-infective agents in HLT41acZ-1IIIB cells, showing no cytotoxicity at the active concentrations.